Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
409 stopped studies mapped to Mature B-Cell Non-Hodgkin Lymphoma and descendants · 88% state a reason
Over the 409 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With… | Phase 2 | terminated | May 28, 2007 | Rush University Medical Center | Lack of accrual and interest in study | Enrollment / accrual |
| NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse… | Phase 1 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | In a limited number of patients, no additional activity was evident for the combination vs.… | Other (stated, no rule matched) |
| NCT01662102 | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | Phase 3 | terminated | Aug 10, 2012 | Spectrum Pharmaceuticals, Inc | Sponsor decision | Sponsor / business decision |
| NCT03585725 | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and… | Early Phase 1 | terminated | Jul 13, 2018 | Weill Medical College of Cornell University | low accrual | Enrollment / accrual |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Jun 13, 2005 | Gilead Sciences | low accrual | Enrollment / accrual |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | Phase 1 | terminated | Nov 19, 2012 | Gilead Sciences | Study was stopped due to insufficient efficacy and very slow accrual | Efficacy / futility |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | Phase 1 / Phase 2 | withdrawn | Apr 12, 2010 | Gilead Sciences | No subjects enrolled | Enrollment / accrual |
| NCT03873025 | A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse…(PLACARD) | Phase 1 / Phase 2 | withdrawn | Mar 13, 2019 | University College, London | There are insufficent funds to open the trial and start recruiting patients due to the impact of… | COVID-19 / pandemic |
| NCT02489123 | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Phase 2 | terminated | Jul 2, 2015 | University of Washington | Accrual goal not met | Enrollment / accrual |
| NCT01434472 | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell… | Phase 2 | terminated | Sep 15, 2011 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
| NCT03178201 | TGR1202 in Relapsed and Refractory Follicular Lymphoma | Phase 2 | terminated | Jun 6, 2017 | Columbia University | PI left institution | Investigator |
| NCT02928510 | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic… | — | terminated | Oct 10, 2016 | Jonsson Comprehensive Cancer Center | withdrawn by sponsor | Other (stated, no rule matched) |
| NCT02323230 | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing… | Phase 2 | terminated | Dec 23, 2014 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | new study | Other (stated, no rule matched) |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | Phase 1 | terminated | Jul 9, 2018 | M.D. Anderson Cancer Center | Study halted prematurely | Other (stated, no rule matched) |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | May 18, 2010 | Dana-Farber Cancer Institute | Per protocol, Phase II is to be terminated early if a less than 5% of the Phase II participants… | Enrollment / accrual |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT02576275 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in… | Phase 3 | withdrawn | Oct 15, 2015 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of…(REAL) | — | terminated | Apr 10, 2020 | SecuraBio | Strategy Change | Sponsor / business decision |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Phase 1 | terminated | Jul 26, 2018 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02309515 | Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic… | Phase 2 | terminated | Dec 5, 2014 | Mayo Clinic | Slow Accrual | Enrollment / accrual |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell… | Phase 1 / Phase 2 | terminated | Jul 2, 2017 | Acerta Pharma BV | Sponsor's decision not to pursue further development of the combination in DLBCL | Sponsor / business decision |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large… | Phase 1 | terminated | Jul 26, 2011 | Novartis Pharmaceuticals | Study terminated due to enrolment challenges and availability of other options for DLBCL patients.… | Safety / toxicity |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator,…(Javelin DLBCL) | Phase 3 | terminated | Nov 1, 2016 | Pfizer | Study was terminated due to closure of study arms following futility analysis and difficulty in… | Efficacy / futility |
| NCT02483000 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating… | Phase 1 | terminated | Jun 26, 2015 | Fred Hutchinson Cancer Center | Closed early due to lack of funding | Funding |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib… | Phase 2 | terminated | Feb 27, 2013 | Gilead Sciences | Sponsor's decision to discontinue development of entospletinib. | Sponsor / business decision |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R… | Phase 1 | withdrawn | Sep 19, 2019 | Second Affiliated Hospital of Xi'an Jiaotong University | Production plan adjustment | Other (stated, no rule matched) |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | N/A | withdrawn | Aug 7, 2020 | Wake Forest University Health Sciences | Principal investigator decided not to pursue trial | Investigator |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Phase 1 / Phase 2 | terminated | Jan 31, 2017 | Sunesis Pharmaceuticals | Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib… | Sponsor / business decision |
| NCT04293900 | Diet, Physical Activity and Body Composition Changes During R-CHOP(R-CHOP-OS) | — | withdrawn | Mar 3, 2020 | George Washington University | Study never started due to COVID pandemic and lack of study funding. | COVID-19 / pandemic |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by… | Phase 1 / Phase 2 | terminated | Jul 21, 2017 | The Lymphoma Academic Research Organisation | Stop of drug development | Other (stated, no rule matched) |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and… | Phase 1 / Phase 2 | withdrawn | Oct 27, 2011 | Louisiana State University Health Sciences Center Shreveport | Investigator has relocated to MD Anderson | Investigator |
| NCT03617484 | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | Phase 2 | withdrawn | Aug 6, 2018 | University of Michigan Rogel Cancer Center | Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to… | COVID-19 / pandemic |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory… | Phase 2 | terminated | Feb 21, 2013 | Gilead Sciences | Study was terminated due to safety measures. | Safety / toxicity |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT03719560 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma(BrUOG-377) | Phase 2 | withdrawn | Oct 25, 2018 | Brown University | lack of funding | Funding |
| NCT00901927 | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk… | Phase 2 | terminated | May 14, 2009 | M.D. Anderson Cancer Center | Study was closed early due to toxicity | Safety / toxicity |
| NCT01077518 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent…(A+B) | Phase 3 | terminated | Mar 1, 2010 | Novartis Pharmaceuticals | The study was terminated early as it did not meet the Primary efficacy objective after primary… | Efficacy / futility |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Phase 1 | withdrawn | Aug 2, 2019 | Dana-Farber Cancer Institute | Business development reasons. | Sponsor / business decision |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy,… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2018 | M.D. Anderson Cancer Center | Lack of Funding | Funding |
| NCT03269552 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia… | Phase 2 | terminated | Aug 31, 2017 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT03670901 | A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With… | Phase 3 | terminated | Sep 14, 2018 | JHL Biotech, Inc. | The development was stopped due to company's strategy consideration | Sponsor / business decision |
| NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With… | N/A | terminated | May 22, 2014 | Masonic Cancer Center, University of Minnesota | Replaced by another study. | Other (stated, no rule matched) |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 | terminated | Aug 20, 2001 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01021423 | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion…(RENEW) | Phase 3 | terminated | Nov 30, 2009 | Celgene | Terminated by sponsor due to new unpublished data that rendered the current design of the study no… | Safety / toxicity |
| NCT01754870 | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by… | Phase 2 | withdrawn | Dec 21, 2012 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT02776891 | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH… | Phase 2 | withdrawn | May 18, 2016 | University of California, San Francisco | Unexpected dose production issues prevented study start up | Other (stated, no rule matched) |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | Phase 1 | terminated | May 27, 2016 | Michael Choi | lack of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 4, 2021source: clinicaltrials